Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU)

被引：2
|
作者：
Moulard, Odile [1 ]
Mehta, Jyotsna [2 ]
Olivares, Robert [1 ]
Iqbal, Usman [2 ]
Mesa, Ruben A. [3 ]
机构：
[1] Sanofi, Global Evidence & Value Dev, Chilly Mazarin, France
[2] Sanofi, Global Evidence & Value Dev, Cambridge, MA USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1744.1744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1744
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Leukemogenic risk of hydroxyurea (HU) therapy in polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM).
    Nand, S
    Stock, W
    Godwin, J
    Fisher, S
    BLOOD, 1995, 86 (10) : 3181 - 3181
  • [12] Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Giles, Jennifer L. K.
    Pitou, Celine
    Zimmermann, Annamaria Hayden
    Price, Gregory L.
    Walgreen, Richard A.
    Prchal, Josef
    BLOOD, 2013, 122 (21)
  • [13] Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis
    Wanquet, Anne
    Courtier, Frederic
    Guille, Arnaud
    Carbuccia, Nadine
    Garnier, Severine
    Adelaide, Jose
    Gelsi-Boyer, Veronique
    Mozziconacci, Marie Joelle
    Rey, Jerome
    Vey, Norbert
    Birnbaum, Daniel
    Murati, Anne
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1289 - 1293
  • [14] MANAGEMENT OF POLYCYTHEMIA-VERA, ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS WITH HYDROXYUREA
    LOFVENBERG, E
    WAHLIN, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1988, 41 (04) : 375 - 381
  • [15] Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia
    Johansson, P
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (03): : 171 - 173
  • [16] Analysis of the Impact and Burden of Illness of Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the US
    Mehta, Jyotsna
    Wang, Hongwei
    Iqbal, Usman
    Mesa, Ruben A.
    BLOOD, 2012, 120 (21)
  • [17] Usefulness of spontaeous colony formation for diagnosis of polycythemia vera (PV) and essential thrombocythemia (ET)
    Scalzulli, PR
    Morelli, A
    Nobile, M
    DArena, G
    Perla, G
    Carotenuto, M
    Musto, P
    BLOOD, 1996, 88 (10) : 385 - 385
  • [18] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
    Gowin, Krisstina L.
    Dueck, Amylou C.
    Mascarenhas, John O.
    Hoffman, Ronald
    Reeder, Craig B.
    Camoriano, John
    Gano, Katherine
    Ghurye, Vineta
    Reddy, Sravan Nagi
    Koenig, Patricia
    Fauble, Veena
    Tibes, Raoul
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [19] Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
    Mora, Barbara
    Giorgino, Toni
    Guglielmelli, Paola
    Rumi, Elisa
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami
    Gotlib, Jason
    Kiladjian, Jean Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Barraco, Daniela
    Pietra, Daniela
    Barbui, Tiziano
    Rotunno, Giada
    Vannucchi, Alessandro Maria
    Passamonti, Francesco
    LEUKEMIA RESEARCH, 2018, 69 : 100 - 102
  • [20] Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
    Ogasawara, Ken
    Zhou, Simon
    Krishna, Gopal
    Palmisano, Maria
    Li, Yan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 891 - 898
12345